Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: YPEL5

Summary for YPEL5

Gene information	Gene symbol	YPEL5
	Ensembl ID	ENSG00000119801
	Entrez ID	51646
	Gene name	yippee like 5
	Synonyms	CGI-127
	Gene type	protein_coding
	UniProtAcc	P62699

Top

Dataset with differentially expressed gene: YPEL5

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	1.77754	2.06e-24
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.628412	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.364389	1.84e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.435653	6.26e-19
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.27244	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.430825	2.22e-09
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.378302	5.15e-30
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.595949	4.83e-37
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.334051	1.15e-12
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.304383	1.26e-29
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mast cells	-0.868317	1.68e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.485375	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.25907	3.62e-05
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.418638	6.66e-22
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.906347	1.02e-10
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.69006	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.6058	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.43819	1.27e-11
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.278722	1.26e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.450663	3.59e-16
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.473215	3.15e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.35407	1.37e-04
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.427245	2.86e-07
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.350731	2.11e-08
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.594317	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.624578	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.419878	3.87e-07
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.769944	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.495503	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.750666	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.717704	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.567292	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.480086	2.00e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.495525	3.11e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.284186	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.668979	1.04e-32
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.531704	2.74e-11
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.595531	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	-0.394493	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.2788	4.07e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.563999	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.285842	3.75e-14
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.62786	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.360101	2.24e-18
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.421069	7.17e-18

Top

Expression of YPEL5 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to YPEL5

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating YPEL5

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
YPEL5	hsa-miR-3688-3p	99.0227	NM_001127399
YPEL5	hsa-miR-5093	98.748	NM_001127399
YPEL5	hsa-miR-542-3p	95.8208	NM_001127399
YPEL5	hsa-miR-4495	94.0846	NM_001127399
YPEL5	hsa-miR-561-3p	93.022	NM_001127399
YPEL5	hsa-miR-30c-5p	92.9545	NM_001127399
YPEL5	hsa-miR-30b-5p	92.9545	NM_001127399
YPEL5	hsa-miR-30e-5p	92.9545	NM_001127399
YPEL5	hsa-miR-30d-5p	92.9545	NM_001127399
YPEL5	hsa-miR-30a-5p	92.9545	NM_001127399
YPEL5	hsa-miR-18b-5p	92.4903	NM_001127399
YPEL5	hsa-miR-18a-5p	92.4903	NM_001127399
YPEL5	hsa-miR-3671	91.4563	NM_001127399
YPEL5	hsa-miR-4645-3p	91.3028	NM_001127399
YPEL5	hsa-miR-4735-3p	91.1684	NM_001127399
YPEL5	hsa-miR-432-3p	90.4111	NM_001127399
YPEL5	hsa-miR-629-5p	89.9119	NM_001127399
YPEL5	hsa-miR-621	89.6791	NM_001127399
YPEL5	hsa-miR-297	89.5786	NM_001127399
YPEL5	hsa-miR-6880-5p	89.4892	NM_001127399
YPEL5	hsa-miR-6124	87.1344	NM_001127399
YPEL5	hsa-miR-6873-3p	86.4163	NM_001127399
YPEL5	hsa-miR-5683	85.5997	NM_001127399
YPEL5	hsa-miR-6508-5p	85.5991	NM_001127399
YPEL5	hsa-miR-30a-3p	84.6848	NM_001127399
YPEL5	hsa-miR-30d-3p	84.6848	NM_001127399
YPEL5	hsa-miR-30e-3p	84.6848	NM_001127399
YPEL5	hsa-miR-4720-3p	84.4974	NM_001127399
YPEL5	hsa-miR-9983-3p	83.859	NM_001127399
YPEL5	hsa-miR-3646	83.632	NM_001127399
YPEL5	hsa-miR-520b-5p	83.3499	NM_001127399
YPEL5	hsa-miR-519a-2-5p	83.3499	NM_001127399
YPEL5	hsa-miR-548q	83.0411	NM_001127399
YPEL5	hsa-miR-548h-3p	83.0355	NM_001127399
YPEL5	hsa-miR-548ac	83.0355	NM_001127399
YPEL5	hsa-miR-548z	83.0355	NM_001127399
YPEL5	hsa-miR-548d-3p	83.0355	NM_001127399
YPEL5	hsa-miR-548bb-3p	83.0355	NM_001127399
YPEL5	hsa-miR-513b-3p	82.2952	NM_001127399
YPEL5	hsa-miR-3160-3p	82.0434	NM_001127399
YPEL5	hsa-miR-4676-5p	81.6399	NM_001127399
YPEL5	hsa-miR-575	81.6399	NM_001127399
YPEL5	hsa-miR-6794-3p	81.5666	NM_001127399
YPEL5	hsa-miR-7851-3p	81.4189	NM_001127399

Page: 1

Top

Motifs and transcription factors (TFs) regulating YPEL5

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
YPEL5	transfac_pro__M04595	SALL2 (directAnnotation).
YPEL5	transfac_pro__M08803	CREM (directAnnotation).
YPEL5	transfac_pro__M06071	ZNF814 (directAnnotation).
YPEL5	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
YPEL5	metacluster_126.14	ZBTB12; ZBTB12 (directAnnotation).
YPEL5	transfac_pro__M05403	ADNP2 (inferredBy_Orthology).
YPEL5	metacluster_161.18	DLX6 (directAnnotation).
YPEL5	metacluster_161.21	GBX2 (directAnnotation).
YPEL5	metacluster_161.34	MNX1 (directAnnotation).
YPEL5	transfac_pro__M04616	ISL1 (directAnnotation). LHX3 (inferredBy_Orthology).
YPEL5	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
YPEL5	transfac_pro__M05798	ZNF517 (directAnnotation).
YPEL5	hocomoco__GSC2_HUMAN.H11MO.0.D	GSC2 (directAnnotation).
YPEL5	jaspar__MA1967.1	TFAP4 (directAnnotation).
YPEL5	jaspar__MA1125.1	ZNF384 (directAnnotation).
YPEL5	hocomoco__BPTF_HUMAN.H11MO.0.D	BPTF (directAnnotation).
YPEL5	metacluster_145.6	ZNF79; ZNF79 (directAnnotation).
YPEL5	jaspar__MA1460.1	YY1 (inferredBy_Orthology).
YPEL5	transfac_pro__M00652	NRF1 (directAnnotation).
YPEL5	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
YPEL5	hdpi__EBF1	EBF1 (directAnnotation).
YPEL5	metacluster_101.3	MYB (directAnnotation).
YPEL5	transfac_pro__M04950	EGR1 (directAnnotation).
YPEL5	metacluster_33.8	BRCA1; CHD2; CHD2; ETS1; NR3C1; ZBED1; ZBED1; ZBED1; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33; ZBTB33 (directAnnotation). CHD2; ZBTB33 (inferredBy_Orthology).
YPEL5	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
YPEL5	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
YPEL5	transfac_pro__M06259	ZNF91 (directAnnotation).
YPEL5	hdpi__TIMELESS	TIMELESS (directAnnotation).
YPEL5	taipale_tf_pairs__E2F1_EOMES_RGGTGTNNNGGCGSNNTNNCRSNN_CAP	E2F1; EOMES (directAnnotation).
YPEL5	transfac_pro__M06340	ZNF790 (directAnnotation).
YPEL5	homer__NANTGCSGCA_Zfp57	ZFP57 (directAnnotation).
YPEL5	metacluster_22.37	BACH1 (directAnnotation).
YPEL5	metacluster_22.20	MAFG (directAnnotation).
YPEL5	metacluster_22.33	MAFK (inferredBy_Orthology).
YPEL5	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
YPEL5	tfdimers__MD00069	IKZF1; PDX1 (directAnnotation).
YPEL5	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
YPEL5	transfac_pro__M04916	TAF1 (directAnnotation).
YPEL5	transfac_pro__M12697	ZNF142 (directAnnotation).
YPEL5	metacluster_135.11	NR2C2 (directAnnotation).
YPEL5	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
YPEL5	metacluster_160.20	JUND; PRDM15 (directAnnotation).
YPEL5	metacluster_198.3	ZFP64 (directAnnotation).
YPEL5	metacluster_141.5	NR3C1; THAP1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZNF597 (directAnnotation). YY1; YY1; YY1; YY2; ZFP42 (inferredBy_Orthology).
YPEL5	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
YPEL5	jaspar__MA0185.1	DEAF1 (inferredBy_Orthology).
YPEL5	metacluster_61.1	DEAF1; DEAF1 (directAnnotation).
YPEL5	cisbp__M00788	ZFY (inferredBy_Orthology).
YPEL5	kznf__ZNF213_Schmitges2016_RCADE	ZNF213 (directAnnotation).
YPEL5	metacluster_175.1	ZNF283 (directAnnotation).

Page: 1 2 3 4 5 6 7

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."